Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

27 results about "Factor H" patented technology

Factor H is a member of the regulators of complement activation family and is a complement control protein. It is a large (155 kilodaltons), soluble glycoprotein that circulates in human plasma (at typical concentrations of 200–300 micrograms per milliliter). Its principal function is to regulate the alternative pathway of the complement system, ensuring that the complement system is directed towards pathogens or other dangerous material and does not damage host tissue. Factor H regulates complement activation on self cells and surfaces by possessing both cofactor activity for the Factor I mediated C3b cleavage, and decay accelerating activity against the alternative pathway C3-convertase, C3bBb. Factor H exerts its protective action on self cells and self surfaces but not on the surfaces of bacteria or viruses. This is thought to be the result of Factor H having the ability to adopt conformations with lower or higher activities as a cofactor for C3 cleavage or decay accelerating activity. The lower activity conformation is the predominant form in solution and is sufficient to control fluid phase amplification. The more active conformation is thought to be induced when Factor H binds to glycosaminoglycans (GAGs) and or sialic acids that are generally present on host cells but not, normally, on pathogen surfaces ensuring that self surfaces are protected whilst complement proceeds unabated on foreign surfaces.

Anti-C5 antibodies fused to factor H for use in the treatment of complement-mediated diseases

The present application provides a method for treating a complement-mediated disease in a human individual, the method comprising administering to the individual an effective amount of a fusion protein comprising: i) an antibody portion that specifically binds to human C5; and ii) factor H (FH) or a functional fragment thereof. The complement-mediated disease can be, for example, paroxysmal nocturnal hemoglobinuria (PNH) syndrome, C3 glomerulopathy (C3G), IgA nephropathy (IgAN), and thrombotic microangiopathy secondary to systemic lupus erythematosus (SLE-TMA).
Owner:KIRA PHARMACEUTICALS (US) LLC

Meningococcal protein-based vaccine formulations and methods for making same

PendingCN121038809AAntibacterial agentsDepsipeptidesMeningococcal carriageImmunogenicity
The present invention provides fusion proteins having the desire to reduce Factor H binding, in particular the present invention provides optimized processes for the manufacture of fusion proteins and formulations comprising fusion proteins. The present invention provides an effective platform process for the manufacture of an effective vaccine formulation against Neisseria meningitidis, which meets a variety of criteria, including improved immunogenicity, safety, stability, and burdenability.
Owner:SERUM INST OF INDIA PTE LTD

Kidney active fusion proteins and methods of treatment using the same

PCT designated stageWO2026135714A1Connective tissue peptidesPeptide/protein ingredientsSegmental glomerulosclerosisRenal glomerulus
Described herein are fusion proteins which include factor H functional domains and may include VHH domains and integrin binding domains, and the use of such fusion proteins in methods of treatment of focal segmental glomerulosclerosis.
Owner:ALEXION PHARMACEUTICALS INC

Compositions and methods for treating complement-mediated diseases

ActiveCN115976105BDiseasePharmacy medicine
The present invention relates to compositions and methods for treating complement-mediated diseases. Provided are recombinant vectors having an expression cassette comprising a modified human factor H (hfH) gene, wherein the hfH gene encodes a hfH protein variant comprising SCR1-4, 19-20, and one or more of: SCR7, SCR17, and / or SCR18. Also provided are pharmaceutical compositions comprising the vectors and their use in treating AMD and / or other complement-related diseases.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Sialylated human factor h protein for treatment of paroxysmal nocturnal hemoglobinuria

PendingAU2025213816A1Paroxysmal AFThrombocyte aggregation
The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof for use in treating paroxysmal nocturnal hemoglobinuria, for treating thromboinflammation, for treating pathological platelet aggregate formation for treating microangiopathy, and / or for treating Long COVID. Combination with a C5 inhibitor, e.g. eculizumab, is also envisaged.
Owner:ELEVA GMBH

Methods of treating ocular diseases using engineered polypeptides comprising complement factor h and factor h-like protein domains

PendingUS20260201001A1DiseaseGeographic atrophy
Methods of treating ocular diseases such as age-related macular degeneration may include the administration of peptides comprising complement factor H and factor H-like protein domains to reduce an amount of geographic atrophy in a subject in need thereof. These methods may be administered by intraocular, intervascular or subcutaneous injection.
Owner:CHARACTER BIOSCIENCES INC

Factor H potentiating antibodies and uses thereof

The invention relates to novel isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H. The invention further relates to the use of such antibodies and fragments for inhibiting complement activation and treatment of disorders associated with complement activation.
Owner:SANQUIN BLOOD SUPPLY FOUND

Modified factor H binding protein

ActiveUS12497432B2Antibacterial agentsDepsipeptidesColonisationVirology
The invention relates to a modified factor H binding protein (fHbp), comprising fHbp, or a variant thereof, modified with the addition of at least one exogenous peptide loop; and associated nucleic acid, compositions, and uses. The invention further relates to treatment or prevention of a pathogenic infection or colonisation of a subject using the modified factor H binding protein (fHbp).
Owner:OXFORD UNIVERSITY INNOVATION LTD

Adjuvanted immunogenic composition against neisseria meningitidis b

PendingUS20260048113A1Antibacterial agentsDepsipeptidesAdjuvantMeningitidis neisseria
The disclosure relates to an immunogenic composition comprising a combination of Neisseria meningitidis serogroup B antigens, said combination comprising at least one factor H binding protein (fHBP) A and at least one factor H binding protein (fHBP) B, and an aluminum hydroxyphosphate (AlPO4) adjuvant, the AlPO4 adjuvant being selected as having a point of zero charge (PZC) below 5.
Owner:SANOFI PASTEUR INC

Neisseria meningitidis compositions and methods thereof

PendingUS20260124287A1Antibacterial agentsInorganic non-active ingredientsNeisseria meningitidisMeningitides
In one aspect, the disclosure relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide, and methods of use thereof. The disclosure further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
Owner:PFIZER INC

Engineered complement factor H related protein and application thereof

The invention discloses an engineered complement factor H-related protein and application thereof, the engineered complement factor H-related protein is a polypeptide containing SCR1-2 of a factor H-related protein 1 (FHR1) or a functional fragment thereof, and the polypeptide has a better effect on treatment of complement-related diseases. The invention also discloses a fusion protein containing the polypeptide, or a nucleic acid molecule, a carrier or a cell for coding the polypeptide, and also discloses a pharmaceutical composition and a kit containing the substance.
Owner:PEKING UNIVERSITY FIRST HOSPITAL (PEKING UNIVERSITY FIRST CLINICAL MEDICAL COLLEGE)

AAV variant for the treatment of complement imbalance

PendingJP2026518295AOrganic active ingredientsSenses disorderGeographic atrophyTransgene
Recombinant AAV (rAAV) comprising a variant adeno-associated virus (AAV) capsid and a transgene encoding a human factor H variant is provided. Also provided are a method for delivering the transgene to the retina, and a method for treating dry age-related macular degeneration and geographic atrophy secondary to age-related macular degeneration by contacting retinal cells with rAAV. The variant AAV capsid protein may contain a peptide insertion ("heterogeneous peptide" or "peptide insertion") of about 7 to 20 amino acids within the GH loop of the capsid protein, preferably within the surface-exposed region of the GH loop, compared to the corresponding parental AAV capsid protein.
Owner:4D MOLECULAR THERAPEUTICS INC

Sialylated human factor H proteins and therapeutic uses thereof

The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragment or biologically active sialylated variant thereof. The invention also relates to methods of producing such proteins in vitro, and methods of using such proteins for the treatment of complement-mediated diseases, such as C3 glomerulopathy, atypical hemolytic uremic syndrome or age-related macular degeneration.
Owner:ELEVA GMBH

Factor H vectors and uses thereof

Aspects of the disclosure relate to compositions and methods for expressing a Factor H protein (or a variant thereof) in a cell or subject. In some embodiments, the disclosure provides isolated nucleic acids and rAAVs comprising a transgene encoding a Factor H protein variant and one or more regulatory sequences. In some embodiments, compositions described herein are useful for treating subjects having diseases associated with Factor H deficiency.
Owner:UNIV OF MASSACHUSETTS

Subcutaneous administration of sialylated human factor h protein

PCT designated stageWO2026087607A1Senses disorderPeptide/protein ingredientsMacula lutea degenerationParoxysmal nocturnal hemoglobinuria
The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof, wherein the protein does not comprise trisia lylated N-glycans of the structure A3G3S3 (NaNaNa), for use in a method of treatment, wherein the method of treatment involves administering subcutaneously said in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof subcutaneously. The methods of treatment comprise treating complement-mediated diseases such as C3 glomerulopathy (C3G), atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD) or paroxysmal nocturnal hemoglobinuria.
Owner:ELEVA GMBH

Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases

The present application provides methods of treating a complement-mediated disease in a human individual, comprising administering to the individual an effective amount of a fusion protein comprising i) an antibody moiety that specifically binds to human C5 and ii) a Factor H (FH) or functional fragment thereof. The complement-mediated disease can be, for example, paroxysmal nocturnal hemoglobinuria (PNH) syndrome, C3 glomerulopathy (C3G), IgA nephropathy (IgAN), and thrombotic microangiopathy secondary to systemic lupus erythematosus (SLE-TMA).
Owner:KIRA PHARMACEUTICALS (US) LLC

Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases

The present application provides novel dosing regimens for methods of treating a complement-mediated disease in a human individual, comprising administering to the individual an effective amount of a fusion protein comprising i) an antibody moiety that specifically binds to human C5 and ii) a Factor H (FH) or functional fragment thereof. The complement-mediated disease can be, for example, paroxysmal nocturnal hemoglobinuria (PNH) syndrome, C3 glomerulopathy (C3G), IgA nephropathy (IgAN), thrombotic microangiopathy secondary to systemic lupus erythematosus (SLE-TMA), and thrombotic microangiopathy secondary to lupus nephritis (LN-TMA).
Owner:KIRA PHARMACEUTICALS (US) LLC

Compositions comprising factor h-like protein variants for use in treating ocular diseases

PendingUS20260116937A1Senses disorderAntibody mimetics/scaffoldsShort Consensus RepeatDisease
Engineered polypeptides for use in treating ocular diseases may include peptides having short consensus repeat (SCR) regions of complement factor H and Factor H-like proteins. Exemplary peptides may include a first region consisting essentially of complement factor H domains SCR1-SCR7 and a second region that comprises at least complement factor H domain SCR7.
Owner:CHARACTER BIOSCIENCES INC

Siarylated human factor H protein and its therapeutic use

summary The present invention relates to in vitro sialylated human factor H protein, or to biologically active sialylated fragments or biologically active sialylated variants thereof. The present invention also relates to methods for producing such proteins in vitro, and to methods for using such proteins in the treatment of complement-mediated diseases such as C3 glomerulosis, atypical hemolytic uremic syndrome, or age-related macular degeneration.
Owner:ELEVA GMBH

Sialylated human factor h protein for treatment of paroxysmal nocturnal hemoglobinuria

PendingCA3318699A1Paroxysmal AFThrombocyte aggregation
The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof for use in treating paroxysmal nocturnal hemoglobinuria, for treating thromboinflammation, for treating pathological platelet aggregate formation for treating microangiopathy, and / or for treating Long COVID. Combination with a C5 inhibitor, e.g. eculizumab, is also envisaged.
Owner:ELEVA GMBH

Diagnostic test for the detection of bladder cancer in urine

It is provided a method of diagnosing bladder cancer in a subject comprising measuring in a urine sample the protein level of expressions of at least two protein markers selected from complement factor H (CFH), Fibrinogen β (FGB), alpha-2-macroglobulin (A2M) and pancreatic alpha-amylase (AMY2A) and a kit for same. The method and kit allow to monitor and / or diagnose high-grade bladder cancer in patients suspected of having bladder cancer, having or not hematuria.
Owner:TRANSFERTECH SSH S E C

Neisserial surface protein a (NSPA) variants and methods of use thereof

Variant Neisserial surface protein A (NspA) with reduced binding to human factor H (FH) are provided. These variants are useful for eliciting antibodies that are bactericidal for at least one strain of N. meningitidis. Compositions comprising such proteins, and methods of use of such proteins are disclosed.
Owner:RGT UNIV OF CALIFORNIA

Meningococcal hexavalent combination vaccine

PCT designated stageWO2025224732A1Bacterial antigen ingredientsAntibacterial agentsGlycoprotein bindingMeningococcal carriage
The present invention relates to combination vaccine comprising hexavalent serogroup of Neisseria meningitidis for prevention and prophylaxis of infection caused by meningococcal bacteria. The present invention relates to a hexavalent combination vaccine comprising serogroups A, B, C, Y, W, X of Neisseria meningitidis. The present invention relates to a hexavalent combination vaccine comprising polysaccharide- protein conjugate of serogroups A, C, Y, W, X and proteins of serogroup B of Neisseria meningitidis. The present invention specifically relates to a hexavalent combination vaccine comprising polysaccharide- protein conjugate of serogroup A, C, Y, W, X and mutated Factor H binding proteins (fHbp) of serogroup B of Neisseria meningitidis. The present invention further relates to the composition, use and process of preparation of hexavalent combination vaccine.
Owner:TECHINVENTION LIFECARE PRIVATE LIMITED

AAV variants for treatment of complement disorders

A recombinant AAV (rAAV) comprising a variant adeno-associated virus (AAV) capsid and a transgene encoding a human factor H variant is provided. Also provided are methods of delivering a transgene to the retina, as well as methods of treating dry age-related macular degeneration and map-like atrophy secondary to an age-related macular degeneration disorder by contacting retinal cells with rAAV.
Owner:4D MOLECULAR THERAPEUTICS INC

Improved vaccinia virus vectors

Disclosed herein are polynucleotides encoding fusion proteins, the fusion proteins comprising a vaccinia virus envelope protein, such as A13 or part thereof and at least one complement regulatory protein, such as CD35, CD55, CD59, CD46, CR1, Factor H, VCP, MOPICE, SPICE and CCPH, or a functional fragment thereof. Modified vaccinia virus vectors and vaccinia virus virions are also disclosed, as are therapeutic uses and methods for treatment of cancers and / or proliferative diseases or disorders.
Owner:STRATOSVIR LTD

Treatment of anca-associated vasculitis

PendingCN122341383AComplement S-ProteinAntiendomysial antibodies
Compounds, compositions, and methods are provided for treating ANCA-associated vasculitis (AAV) in patients of need. The method includes administering an effective amount of a composition comprising a fusion protein construct comprising: an antibody that specifically binds to complement protein 3d (c3d), and two complement modulatory peptides, each of the complement modulatory peptides comprising a bioactive fragment of factor H.
Owner:AKEBIA THERAPEUTICS INC